As a model system, we utilized a highly plastic, patient-derived M397 BRAFV600E mutant melanoma cell line, which has been shown to reversibly transition between drug-naive and drug-resistant states upon treatment with a BRAF inhibitor8,10,62. Here, BRAF is linked to melanoma.